Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions

Melanoma Research

Volumn 16, Issue 5, 2006, Pages 435-444

  Kuźbicki, Łukasz ^a   Aładowicz, Ewa ^a   Chwirot, Barbara W ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Cyclin dependent kinase 2; Immunohistochemistry; Melanoma progression; Molecular marker

Indexed keywords

CYCLIN DEPENDENT KINASE 2; FORMALDEHYDE; PARAFFIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CELL LINE; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN DEFECT; STATISTICAL SIGNIFICANCE;

CELL CYCLE; CYCLIN-DEPENDENT KINASE 2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MELANOCYTES; MELANOMA; NEVUS, PIGMENTED; PROGNOSIS; SKIN NEOPLASMS;

EID: 33749435923     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000232290.61042.ee     Document Type: Article

References (40)

1. 1 cyclins. Cell 1993; 73:1059-1065.
2. Israels ED, Israels LG. The cell cycle. Stem Cells 2000; 19:88-91.
3. Roberts JM, Sherr CJ. Bared essentials of CDK2 and cyclin E. Nat Genet 2003; 35:9-10.
4. Akiyama T, Ohuchi T, Sumida S, Matsumoto K, Toyoshima K. Phosphorylation of the retinoblastoma protein by cdk2. Proc Natl Acad Sci USA 1992; 89:7900-7904.
5. Zhao J, Dynlacht B, Imai T, Hori T, Harlow E. Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes Dev 1998; 12:456-461.
6. Zhao J, Kennedy BK, Lawrence BD, Barbie DA, Matera AG, Fletcher JA, et al. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev 2000; 14:2283-2297.
7. Perkins ND, Felzien LK, Betts JC, Leung K, Beach CH, Nabel GJ. Regulation of NF-κB by cyclin-dependent kineses associated with the p300 coactivator. Science 1997; 275:523-527.
8. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998; 12:599-606.
9. Shanahan F, Seghezzi W, Parry D, Mahony D, Lees E. Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest. Mol Cell Biol 1999; 19:1460-1469.
10. Keller C, Krude T. Requirement of cyclin/CDK2 and protein phosphatase 1 activity for chromatin assembly factor 1-dependent chromatin assembly during DNA synthesis. J Biol Chem 2000; 275:35512-35521.
11. Coverley D, Laman H, Laskey RA. Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nat Cell Biol 2002; 4:523-528.
12. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan P-K, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103:127-140.
13. Okuda M. The role of nucleophosmin in cenrtosome duplication. Oncogene 2002; 21:6170-6174.
14. Hinchcliffe EH, Sluder G. Two for two: Cdk2 and its role in centrosome doubling. Oncogene 2002; 21:6154-6160.
15. Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markers of tumor proliferation: immunohistochemical studies in breast cancer. Proc Natl Acad Sci USA 1992; 92:5386-5390.
16. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol 2001; 32:89-94.
17. Kim HK, Park I-A, Heo DS, Noh D-Y, Choe K-J, Bang Y-J, et al. Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. EJSO 2001; 27:464-471.
18. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566-1575.
19. Dobashi Y, Shoji M, Jiang S-X, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998; 153:963-972.
20. Mishina T, Dosaka-Akita H, Hommura F, Nishi M, Kojima T, Ogura S, et al. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res 2000; 6:11-16.
21. Hayashi H, Ogawa N, Ishiwa N, Yazawa T, Inayama Y, Ito T, et al. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 2001; 34:59-65.
22. Müller-Tidow C, Metzger R, Kügel K, Diderichs S, Idos G, Thomas M, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001; 61:647-653.
23. Yamanouchi H, Furihata M, Fujita J, Murakami H, Yoshinouchi T, Takahara J, et al. Expression of cyclin E and cyclin D1 in non-small cell lung cancers. Lung Cancer 2001; 31:3-8.
24. Kip1 and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999; 155:1129-1136.
25. Dong Y, Sui L, Tai Y, Sugimoto K, Hirao T, Tokuda M. Prognostic significance of cyclin E overexpression in laryngeal squamous cell carcinomas. Clin Cancer Res 2000; 6:4253-4258.
26. Mihara M, Shintani S, Nakahara Y, Kiyota A, Ueyama Y, Matsumura T, et al. Overexpression of CDK2 is a prognostic indicator of oral cancer progression. Jpn J Cancer Res 2001; 92:352-360.
27. Kato N, Watanabe J, Jobo T, Nishimura Y, Fujisawa T, Kamata Y, et al. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. J Cancer Res Clin Oncol 2003; 129:222-226.
28. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35:25-31.
29. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233-245.
30. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004; 6:565-576.
31. Tang L, Li G, Tron VA, Trotter MJ, Ho VC. Expression of cycle regulators in human cutaneous malignant melanoma. Melanoma Res 1999; 9:148-154.
32. Halaban R. The regulation of normal melanocyte proliferation. Pigment Cell Res 2000; 13:4-14.
33. de Wit NJW, van Muijen GNP, Ruiter DJ. Immunohistochemistry in melanocytic proliferative lesions. Histopathology 2004; 44:517-541.
34. KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 1999; 113:1039-1046.
35. Georgieva J, Sinha P, Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 2001; 54:229-235.
36. Hsu S-M, Soban E. Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. J Histochem Cytochem 1982; 30:1079-1082.
37. Scopsi L, Larsson L-I. Increased sensitivity in peroxidase immunocytochemistry. A comparative study of a number peroxidase visualization methods employing a model system. Histochemistry 1986; 84:221-230.
38. Walker G, Hayward N. No evidence of a role for activating CDK2 mutations in melanoma. Melanoma Res 2001; 11:343-348.
39. Kuźbicki Ł, Sarnecka A, Chwirot BW. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 2006; 16:29-36.
40. Kuźbicki Ł, Gajo B, Chwirot BW. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Res 2006 16:235-243.